Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI)
Source: View publication →
In patients with atrial fibrillation undergoing successful PCI, an edoxaban-based dual antithrombotic strategy was non-inferior to a vitamin K antagonist-based triple therapy strategy regarding major or clinically relevant non-major bleeding, with no significant differences in ischemic events.
Key Findings
Study Design
Study Limitations
Clinical Significance
The trial supports the use of an edoxaban-based dual antithrombotic regimen as a non-inferior and safe alternative to VKA-based triple therapy in patients with atrial fibrillation following PCI, potentially simplifying regimens and reducing the risks associated with prolonged triple antithrombotic therapy.
Historical Context
ENTRUST-AF PCI belongs to a series of randomized trials (including WOEST, PIONEER-AF PCI, RE-DUAL PCI, and AUGUSTUS) that sought to identify the optimal 'antithrombotic sweet spot' by de-escalating antithrombotic intensity—specifically by omitting aspirin—in patients with atrial fibrillation requiring oral anticoagulation who undergo coronary stenting, thereby aiming to maintain ischemic protection while minimizing bleeding risks.
Guided Discussion
High-yield insights from every perspective
Why is a combination of an anticoagulant (like edoxaban) and an antiplatelet (like a P2Y12 inhibitor) necessary for a patient with atrial fibrillation undergoing coronary stenting, rather than using just one or the other?
Key Response
Atrial fibrillation creates a low-flow environment in the atria, leading to 'red clots' primarily composed of fibrin and red blood cells, which require anticoagulants (e.g., Factor Xa inhibitors). Conversely, coronary stenting causes endothelial injury and introduces a foreign body, leading to 'white clots' primarily composed of platelets, which require antiplatelet therapy. ENTRUST-AF PCI demonstrates how to balance these two distinct pathways while minimizing the bleeding risk associated with combining these agents.
In the ENTRUST-AF PCI trial, what was the specific timing for the transition from triple therapy to edoxaban-based dual therapy, and how does this inform your immediate post-operative management of AF patients?
Key Response
Patients were randomized between 4 hours and 5 days after successful PCI. This suggests that while a brief period of triple therapy (including aspirin) occurs periprocedurally, the aspirin can be safely discontinued within the first week. For a resident, this means planning for aspirin cessation at discharge for the majority of AF-PCI patients to adhere to the dual-therapy strategy validated by the trial.
ENTRUST-AF PCI utilized the full 60mg dose of edoxaban (or 30mg if dose-reduction criteria were met). How does this design choice and the resulting ischemic outcomes compare to the PIONEER AF-PCI trial with rivaroxaban, and what does this imply about 'efficacy-focused' vs. 'safety-focused' NOAC dosing in PCI?
Key Response
Unlike PIONEER AF-PCI, which used a reduced dose of rivaroxaban (15mg), ENTRUST-AF PCI used the stroke-prevention dose of edoxaban. While both trials showed safety (reduced bleeding), using the full dose provides more theoretical confidence in preventing systemic embolic events and stroke, although neither trial was individually powered to prove non-inferiority for rare ischemic events like stent thrombosis compared to triple therapy.
Despite meeting its primary safety endpoint for non-inferiority, the Kaplan-Meier curves for bleeding in ENTRUST-AF PCI show an early crossover. What does this suggest about the 'hazard' of the edoxaban-based strategy in the ultra-early phase (first 14 days), and how should this influence your teaching on the 'bleeding-ischemic trade-off'?
Key Response
The trial noted a higher rate of bleeding in the edoxaban group in the first few days (potentially due to the immediate start of full-dose NOAC vs. the time required for VKA to reach therapeutic INR). This serves as a teaching point that the 'safety' of dual therapy is realized over the long term, but the transition period requires vigilance, especially in patients with high immediate post-procedural bleeding risks.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ENTRUST-AF PCI trial used a non-inferiority margin of 1.20 for the hazard ratio of the primary safety endpoint. Critically analyze how the 'as-treated' versus 'intent-to-treat' analyses in this specific trial impact the validity of this margin, especially given the open-label design.
Key Response
In non-inferiority trials, ITT analysis can be anti-conservative because 'noise' (non-compliance or crossover) tends to make groups look more similar, favoring a finding of non-inferiority. PhD researchers would look for consistency across both ITT and per-protocol/as-treated sets; in ENTRUST, the findings were consistent, but the choice of a 20% margin is a subjective clinical-statistical threshold that influences the trial's success.
Considering the 'class effect' established by PIONEER, RE-DUAL, and AUGUSTUS, what is the specific editorial 'value-add' of ENTRUST-AF PCI for the medical literature, and what major limitation would a skeptical reviewer cite regarding its ischemic endpoint analysis?
Key Response
The value-add is the completion of the 'four major NOACs' evidence base for the AF-PCI population, confirming edoxaban is a viable option. However, a skeptical reviewer would flag that the trial was significantly underpowered for ischemic outcomes (MACE), with a wide confidence interval for stent thrombosis, meaning it cannot definitively rule out an increase in coronary events when aspirin is omitted early.
Current ESC and AHA/ACC guidelines give a Class I (Level of Evidence A) recommendation for NOAC-based dual therapy over VKA-based triple therapy. How does ENTRUST-AF PCI specifically support the recommendation to limit aspirin to the 'periprocedural' period only?
Key Response
ENTRUST-AF PCI randomized patients as early as 4 hours post-PCI, providing evidence for the shortest possible duration of triple therapy. This supports the 2020 ESC AF guidelines and 2023 ESC ACS guidelines, which recommend a default strategy of discontinuing aspirin after 1 week (or even at discharge) in patients with AF, moving directly to a NOAC and a P2Y12 inhibitor.
Clinical Landscape
Noteworthy Related Trials
PIONEER AF-PCI
Tested
Rivaroxaban-based therapy
Population
Patients with non-valvular AF undergoing PCI with stenting
Comparator
Vitamin K antagonist (VKA) therapy
Endpoint
Clinically significant bleeding
RE-DUAL PCI
Tested
Dabigatran dual therapy
Population
Patients with AF undergoing PCI with stenting
Comparator
Warfarin-based triple therapy
Endpoint
Major or clinically relevant non-major bleeding
AUGUSTUS
Tested
Apixaban plus P2Y12 inhibitor without aspirin
Population
Patients with AF and recent ACS or PCI
Comparator
VKA plus P2Y12 inhibitor and aspirin
Endpoint
Major or clinically relevant non-major bleeding
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis